Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CVS Stock Forecast 2025-2026
$78.99
Current Price
$100.27B
Market Cap
Buy 23
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to CVS Price Targets
+30.4%
To High Target of $103.00
+17.7%
To Median Target of $93.00
-2.5%
To Low Target of $77.00
CVS Price Momentum
+1.1%
1 Week Change
+2.9%
1 Month Change
+42.2%
1 Year Change
+76.0%
Year-to-Date Change
-7.2%
From 52W High of $85.15
+81.3%
From 52W Low of $43.56
📊 TOP ANALYST CALLS
Did CVS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CVS is one of their latest high-conviction picks.
Latest CVS Stock Price Targets & Analyst Predictions
Based on our analysis of 42 Wall Street analysts, CVS has a bullish consensus with a median price target of $93.00 (ranging from $77.00 to $103.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $78.99, the median forecast implies a 17.7% upside. This outlook is supported by 23 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stephen Baxter at Wells Fargo, projecting a 30.4% upside. Conversely, the most conservative target is provided by Lance Wilkes at Bernstein, suggesting a 2.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVS Analyst Ratings
23
Buy
5
Hold
0
Sell
CVS Price Target Range
Low
$77.00
Average
$93.00
High
$103.00
Current: $78.99
Latest CVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 3, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $100.00 |
| Oct 30, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $95.00 |
| Oct 30, 2025 | Truist Securities | David Macdonald | Buy | Reiterates | $95.00 |
| Oct 30, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $93.00 |
| Oct 30, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $95.00 |
| Oct 24, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $96.00 |
| Oct 14, 2025 | Goldman Sachs | Scott Fidel | Buy | Initiates | $91.00 |
| Oct 14, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $89.00 |
| Oct 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $88.00 |
| Oct 7, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $103.00 |
| Sep 5, 2025 | Bernstein | Lance Wilkes | Market Perform | Maintains | $77.00 |
| Sep 4, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $87.00 |
| Aug 26, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $78.00 |
| Aug 18, 2025 | UBS | Kevin Caliendo | Buy | Upgrade | $79.00 |
| Aug 14, 2025 | Baird | Michael Ha | Outperform | Upgrade | $82.00 |
| Aug 1, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $82.00 |
| Aug 1, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $80.00 |
| Jul 22, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $67.00 |
| Jun 30, 2025 | Jefferies | Brian Tanquilut | Buy | Maintains | $80.00 |
| Jun 2, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $79.00 |
CVS Health Corporation (CVS) Competitors
The following stocks are similar to CVS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CVS Health Corporation (CVS) Financial Data
CVS Health Corporation has a market capitalization of $100.27B with a P/E ratio of 207.9x. The company generates $391.69B in trailing twelve-month revenue with a 0.1% profit margin.
Revenue growth is +7.8% quarter-over-quarter, while maintaining an operating margin of +2.0% and return on equity of +0.6%.
Valuation Metrics
Market Cap
$100.27B
Enterprise Value
$170.97B
P/E Ratio
207.9x
PEG Ratio
-4.9x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+7.8%
Gross Margin
+13.7%
Operating Margin
+2.0%
Net Margin
+0.1%
EPS Growth
+8.4%
Financial Health
Cash/Price Ratio
+11.2%
Current Ratio
0.8x
Debt/Equity
111.8x
ROE
+0.6%
ROA
+2.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CVS Health Corporation (CVS) Business Model
About CVS Health Corporation
What They Do
Provides comprehensive health services and pharmacy solutions.
Business Model
CVS Health operates a vast network of retail pharmacies that generate revenue through the sale of prescription medications, over-the-counter drugs, and health products. Additionally, its pharmacy benefit management division, Caremark, earns income by administering prescription drug plans for insurers and employers. The acquisition of Aetna allows CVS to offer integrated health insurance solutions, enhancing its service offerings and revenue streams.
Additional Information
With thousands of retail locations across the U.S., CVS Health plays a pivotal role in improving healthcare accessibility. The company's diverse portfolio positions it well within the healthcare market, making it a significant player in streamlining medical service delivery.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
219,000
CEO
Mr. J. David Joyner CEBS
Country
United States
IPO Year
1984
Website
www.cvshealth.comCVS Health Corporation (CVS) Latest News & Analysis
Latest News
Quick Summary
CVS Health (CVS) is currently a focus for Zacks.com users, indicating heightened interest and potential upcoming developments for the stock.
Why It Matters
Increased attention on CVS Health indicates potential changes in investor sentiment, which could affect stock volatility and investment strategies moving forward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Trividia Health's TRUE METRIX® Self-Monitoring Blood Glucose Systems have been designated as preferred by CVS Caremark, replacing OneTouch® products for commercial patients in the U.S.
Why It Matters
Trividia Health's TRUE METRIX products gaining preferred status with CVS Caremark enhances market position, potentially boosting sales and market share in the competitive diabetes care segment.
Source: Business Wire
Market Sentiment:
Neutral
CVS Health: Undervalued And Ripe For Growth
5 days ago
Quick Summary
CVS Health's forward P/E is under 12 with a 3.4% dividend yield. Strong Q3 results led to raised 2025 EPS guidance, indicating double-digit earnings growth ahead.
Why It Matters
CVS Health's low valuation, strong Q3 results, raised EPS guidance, and solid dividend yield signal potential for growth and income, attracting investors looking for value opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CVS Pharmacy customers donated over $3 million to local food banks in 2025, with CVS Health increasing its contribution to support Feeding America.
Why It Matters
CVS's $3 million donation enhances its community engagement and social responsibility image, potentially boosting brand loyalty and customer support, which can positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A selection of high-yield dividend stocks includes CVX, VZ, MO, and ARCC, chosen for sustainable dividends and growth potential. CVX and ARCC have positive ratings, while VZ and MO provide high yields.
Why It Matters
The focus on high-yield, sustainable dividend stocks signals potential income stability and growth, appealing to investors seeking reliable returns in a fluctuating market.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CVS Health raised its annual adjusted profit forecast due to increased pharmacy revenues but reported a $5.73 billion writedown on healthcare businesses, including MinuteClinics.
Why It Matters
CVS Health's raised profit forecast signals stronger performance, but the significant writedown indicates underlying challenges, affecting investor confidence and future growth prospects.
Source: Reuters
Market Sentiment:
Neutral
Frequently Asked Questions About CVS Stock
What is CVS Health Corporation's (CVS) stock forecast for 2026?
Based on our analysis of 42 Wall Street analysts, CVS Health Corporation (CVS) has a median price target of $93.00. The highest price target is $103.00 and the lowest is $77.00.
Is CVS stock a good investment in 2026?
According to current analyst ratings, CVS has 23 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $78.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVS stock?
Wall Street analysts predict CVS stock could reach $93.00 in the next 12 months. This represents a 17.7% increase from the current price of $78.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CVS Health Corporation's business model?
CVS Health operates a vast network of retail pharmacies that generate revenue through the sale of prescription medications, over-the-counter drugs, and health products. Additionally, its pharmacy benefit management division, Caremark, earns income by administering prescription drug plans for insurers and employers. The acquisition of Aetna allows CVS to offer integrated health insurance solutions, enhancing its service offerings and revenue streams.
What is the highest forecasted price for CVS CVS Health Corporation?
The highest price target for CVS is $103.00 from Stephen Baxter at Wells Fargo, which represents a 30.4% increase from the current price of $78.99.
What is the lowest forecasted price for CVS CVS Health Corporation?
The lowest price target for CVS is $77.00 from Lance Wilkes at Bernstein, which represents a -2.5% decrease from the current price of $78.99.
What is the overall CVS consensus from analysts for CVS Health Corporation?
The overall analyst consensus for CVS is bullish. Out of 42 Wall Street analysts, 23 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $93.00.
How accurate are CVS stock price projections?
Stock price projections, including those for CVS Health Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 2:49 AM UTC